BioSante (BPAX), Teva (TEVA) Receive FDA Approval for Bio-T-Gel -Bloomberg
Down)
Shares of BioSante Pharma (Nasdaq: BPAX) are rising after hours Tuesday following some Bloomberg headlines which suggest the company and Teva Pharma (Nasdaq: TEVA) have received FDA approval for Bio-T-Gel for men with low testosterone.
After closing at $0.761 this afternoon, shares are now trading around $0.855.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
After closing at $0.761 this afternoon, shares are now trading around $0.855.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40
- Teva Pharma (TEVA) Sees Weaker FY12 Sales, EPS
- Needham & Company Maintains a 'Hold' on Teva Pharma (TEVA); Adjusting Estimates
Create E-mail Alert Related Categories
FDA, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
